Market Position
A market ready
for intervention
70% of adults are overweight. $5.2B spent on healthcare annually. Peptide therapeutics are among the fastest-growing categories in global health. Qatar has zero dedicated providers. This platform will be the first.
$128K GDP per capita. 70% overweight.
Qatar has the economic capacity and healthcare infrastructure to lead in this category. What it lacks is a dedicated peptide therapeutics provider. The global clinical evidence is established. The market is open.
The Gap
Globally, peptide therapeutics are a multi-billion dollar industry. Semaglutide alone exceeded $13B in annual revenue by 2023 and continues to grow. Clinical trials demonstrate 15–24% body weight reduction with these compounds.
Qatar has zero dedicated peptide providers. No structured protocol clinic, no branded adherence platform, no local access to clinically validated compounds. We are building that infrastructure.
The Timing
Post-World Cup, Qatar is investing heavily in health infrastructure and quality of life. The country is building the systems that will define the next decade of wellness in the region.
The platform is positioned to launch while demand is growing and no local competition exists.
Infrastructure first
The brand earns trust through operational credibility, not marketing reach. Influence comes last.
Legal entity, regulatory clarity, clinical infrastructure, and initial partnerships. No public marketing.
- Register commercial entity in Qatar
- Engage regulatory consultant for MoPH
- Secure medical license through physician partnership
- Source 2–3 GMP-certified manufacturing partners
- Build protocol library (8–10 curated stacks)
- Identify first 2–3 facility partnerships
Begin operations with deliberate constraint. Scarcity builds trust.
- Open clinical facility for referral-only
- Launch DTC platform for supplements
- Deploy branded product in partner gyms
- Host private launch event
- Launch protocol management system
- Begin collecting outcome data
Scale operations, deepen partnerships, and prepare for regional expansion.
- Expand to 5–8 facility partnerships
- Register remaining portfolio compounds
- Launch subscription model
- Develop standalone wellness facility
- Build medical advisory board
- Evaluate Saudi Arabia and Bahrain
Conservative projections
Referral-based growth with three complementary revenue channels.
Clinical Facility
Licensed clinic for prescription peptides. Referral-only appointments with full physician oversight. Premium positioning with highest per-client revenue.
DTC Platform
Direct-to-consumer e-commerce for supplement-classified products. Lower barrier to entry, higher volume. QR-linked transparency for every product.
Institutional
Gym partnerships, corporate wellness, and medical clinic integrations. Branded product placement and trainer referral programs with commission structures.
National alignment
The brand is positioned as a health-enabling system that advances Qatar's national health objectives.
Obesity Reduction
70% of Qatari adults are overweight. Metabolic peptides like Retatrutide and Semaglutide deliver 15–24% body weight loss - results validated in large-scale clinical trials.
Physical Activity Increase
43.9% of Qatar's population is physically inactive. These protocols reduce the discomfort of initiation and deliver visible results early, creating the reinforcement necessary for sustained program adherence.
NCD Prevention
69% of Qatar's health burden is preventable chronic disease. Peptides like Semaglutide already have proven cardiovascular benefits in peer-reviewed clinical data.
Talent Attraction
World-class wellness infrastructure positions Qatar as a destination for global professionals who prioritize health optimization.
Get Started
Partner with Qatar's first peptide platform
Whether you are a facility operator, healthcare provider, or individual seeking clinical-grade protocols, the conversation starts here.
Book Consultation